U.S. markets open in 2 hours 17 minutes

Catalyst Pharmaceuticals, Inc. (CPRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.89+0.27 (+4.80%)
At close: 4:00PM EDT

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
http://www.catalystpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees74

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. McEnanyCo-Founder, Chairman, Pres & CEO928.18kN/A1947
Ms. Alicia GrandeChief Accounting Officer, VP, Treasurer & CFO558.27kN/A1971
Dr. Steven R. MillerCOO & Chief Scientific Officer667.17kN/A1962
Dr. Gary IngenitoChief Medical & Regulatory Officer639.29kN/A1956
Mr. Jeffrey Del CarmenChief Commercial Officer507.96kN/A1971
Mr. Brian Elsbernd J.D.Chief Compliance Officer & Chief Legal OfficerN/AN/A1964
Mr. Pete Curry Sr.VP of SalesN/AN/AN/A
Dr. Preethi Sundaram Ph.D.Chief Product Devel. OfficerN/AN/AN/A
Mr. Philip B. SchwartzCorp. Sec.N/AN/A1955
Dr. Charles W. GorodetzkyConsultantN/AN/A1938
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 7. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.